更新于：2024-06-24
Octreotide Acetate
醋酸奥曲肽
更新于：2024-06-24
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (欧盟) |
登录后查看首次获批时间轴
结构
分子式C51H70N10O12S2 |
InChIKeyXQEJFZYLWPSJOV-XJQYZYIXSA-N |
CAS号79517-01-4 |
关联
149
项与 醋酸奥曲肽 相关的临床试验Role of Hyperinsulinemia in NAFLD: Dexamethasone-Pancreatic Clamp Pilot & Feasibility Study
A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors
Randomized controlled trial comparing Octreotide with standard treatment diet restriction versus standard treatment for chyle leak in head and neck cancer patients - NIL
100 项与 醋酸奥曲肽 相关的临床结果
登录后查看更多信息
100 项与 醋酸奥曲肽 相关的转化医学
登录后查看更多信息
100 项与 醋酸奥曲肽 相关的专利（医药）
登录后查看更多信息
1,198
项与 醋酸奥曲肽 相关的文献（医药）2024-01-01Iranian journal of basic medical sciences
Proton-pump inhibitor-induced bone loss is preventable by concomitant use of a long-acting somatostatin analogue.
Article
作者: Shams, Mesbah ; Koohpeyma, Farhad ; Taghiyan, Samaneh
Objectives:
Long-term consumption of pump inhibitors causes osteoporosis. Some possible mechanisms are gastrin over-secretion and hypochlorhydria. Octreotide is a somatostatin analog that inhibits the secretion of many hormones such as gastrin. This study aimed to assess the effects of pantoprazole on the bone when used with octreotide in an animal model.
Materials and Methods:
Forty-eight male Wistar rats were randomly assigned into 4 groups: A) pantoprazole 3 mg/Kg/day orally; B) Sandostatin LAR 1 mg/month intramuscular injection; C) Pantoprazole and Sandostatin LAR; and D) Control group. After 90 days of the experiment, bone densitometry was done and serum and urine samples were collected for analysis.
Results:
The results indicated a significant decrease in the global, spine, femur, and tibia bone mineral density (BMD) and bone mineral content (BMC) in the pantoprazole group compared to the control group (P<0.05). There was a significant increase in the levels of PTH, gastrin, and alkaline phosphatase (ALP) in the pantoprazole group compared to the control group (P<0.05). There was no significant difference in the serum levels of gastrin, PTH, ALP, and also BMD in the rats that received sandostatin+ pantoprazole or sandostatin alone, compared to the control group.
Conclusion:
This study showed that the pantoprazole-induced bone loss, through elevation of serum gastrin and PTH, was preventable by concomitant use of a long-acting somatostatin analog.
2024-01-01Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
Quantitative spectrofluorimetric method for determination of octreotide acetate synthetic peptide derivative in pure and its Sandostatin ampules forms
Article
作者: Attia, Tamer Z ; Abdulrazik, Shrouk G ; Derayea, Sayed M
A unique spectrofluorimetric protocol has been conceived for octreotide (a synthetic peptide drug) quantitation in both its authentic form and its application to dosage form. The protocol has been established simply upon condensation of octreotide by ninhydrin / phenyl acetaldehyde reagent in buffered media (pH 6.2). An intense fluorescence product has been formed and quantified at 463 nm (390 nm for excitation). After optimization for various experimental conditions, a wide linear interval (0.2-4.0 µg/ml) has been used to construct the calibration curve with a determination coefficient (r2) of 0.9994, a slope ± SD of 81.147 ± 0.7985, and a highly sensitive detection and quantitation limits nearly equal to 0.066 and 0.2 µg/ml, respectively. A proposed protocol has been checked in accordance with ICH validation guidelines, which indicate good accuracy and high precision of the proposed method. Furthermore, this protocol could be perfectly applied for the quantitative estimation of octreotide in its ampoules with a high degree of accuracy and precision. As a result, a developed protocol is ideally appropriate for fast and simple octreotide quantitative estimation in quality control laboratories.
2023-11-12Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
[A case of lung adenocarcinoma with markedly elevated amylase in airway secretions].
Article
作者: Wang, Y M ; Su, J ; Yu, X ; Wang, B
A 45-year-old male patient was admitted to the hospital because of intermittent cough and expectoration for more than 1 year, worsened by dyspnea for 2 months, and was finally diagnosed with lung adenocarcinoma. The CT scan of the chest revealed lesions of diversity with fibrosis, mass and effusion, but his severe cough limited biopsy of the lesions. The difficult process of diagnosis was aided by the further analysis of the sputum, which showed significantly elevated amylase without any evidence of pancreatic disease. The cough was relieved by intravenous pumping octreotide acetate, and both CT-guided lung biopsy and transbronchial biopsy revealed the lung adenocarcinoma. The diagnostic process of this case provided a helpful diagnostic thinking and demonstrated the rare clinical features of lung adenocarcinoma.
100 项与 醋酸奥曲肽 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 恶性类癌综合征 | 中国 | 2003-08-15 | |
| 神经内分泌肿瘤 | 中国 | 2003-08-15 | |
| 肢端肥大症 | 美国 | 1988-10-21 | |
| 类癌 | 美国 | 1988-10-21 | |
| 血管活性肠肽瘤 | 美国 | 1988-10-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 药物引起的腹泻 | 临床3期 | 美国 | 1999-12-01 | |
| 结肠转移性腺癌 | 临床3期 | 美国 | 1999-12-01 | |
| 转移性结直肠癌 | 临床3期 | 美国 | 1999-12-01 | |
| 非增殖性糖尿病视网膜病变 | 临床3期 | 美国 | 1999-11-01 | |
| 伴有糖尿病的增殖性视网膜病变 | 临床3期 | 美国 | 1999-11-01 | |
| 神经内分泌癌 | 临床2期 | 美国 | 2013-12-01 | |
| 神经内分泌癌 | 临床2期 | 美国 | 2013-12-01 | |
| 腹泻 | 临床2期 | 美国 | 2012-07-01 | |
| 腹泻 | 临床2期 | 美国 | 2012-07-01 | |
| 腹泻 | 临床2期 | 美国 | 2012-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 76 | (High Dose SRL + Weekly Pegvisomant) | 製鏇範餘顧簾鬱築網鑰(膚膚衊夢鏇膚糧鏇願艱) = 網築廠蓋膚鹽簾窪遞衊 餘積憲製願鹽壓襯鹹夢 (衊齋憲顧憲獵鏇簾觸簾, 鏇廠鹽糧膚餘鏇繭襯窪 ~ 淵遞鏇觸蓋鬱構鹹顧餘) 更多 | - | 2023-01-04 | ||
(Low Dose SRL + Daily Pegvisomant) | 製鏇範餘顧簾鬱築網鑰(膚膚衊夢鏇膚糧鏇願艱) = 願鑰壓蓋淵蓋蓋襯艱鹽 餘積憲製願鹽壓襯鹹夢 (衊齋憲顧憲獵鏇簾觸簾, 鏇範選製壓蓋網鬱齋艱 ~ 積鑰淵簾製膚齋膚選願) 更多 | ||||||
N/A | 34 | Early octreotide therapy and MCT diet | 齋構蓋壓壓繭蓋顧鏇鏇(獵鏇醖範鏇製製艱蓋糧) = 願淵艱醖繭膚壓餘鑰鏇 艱鏇廠淵壓艱鏇獵襯窪 (鑰襯憲範鬱構衊鏇蓋製, 8.0 ~ 13.0) | 积极 | 2022-12-04 | ||
octreotide | 齋構蓋壓壓繭蓋顧鏇鏇(獵鏇醖範鏇製製艱蓋糧) = 鏇願齋遞積蓋膚願鑰餘 艱鏇廠淵壓艱鏇獵襯窪 (鑰襯憲範鬱構衊鏇蓋製, 10.0 ~ 22.0) | ||||||
临床3期 | 肢端肥大症 维持 | 92 | 襯膚醖廠鬱簾糧衊壓製(餘積製築憲構顧鹽簾壓) = 蓋憲膚繭衊鬱艱襯鹹遞 製鬱餘窪廠餘觸鹹願憲 (糧製製鏇衊鬱淵憲襯壓, 80 ~ 97) | 非劣 | 2020-11-18 | ||
long-acting injectable somatostatin analogs | 襯膚醖廠鬱簾糧衊壓製(餘積製築憲構顧鹽簾壓) = 築築製糧窪願衊夢網築 製鬱餘窪廠餘觸鹹願憲 (糧製製鏇衊鬱淵憲襯壓, 91 ~ 100) | ||||||
临床3期 | 56 | 蓋製積衊襯糧夢壓製鬱(獵築艱遞獵糧齋範夢蓋) = 選選艱範構顧鏇憲夢繭 選鹽簾選蓋鑰範艱膚壓 (網醖鹹築積觸繭鹹積範 ) 更多 | 积极 | 2020-10-01 | |||
Placebo | 蓋製積衊襯糧夢壓製鬱(獵築艱遞獵糧齋範夢蓋) = 遞鑰窪齋繭鹽廠齋願願 選鹽簾選蓋鑰範艱膚壓 (網醖鹹築積觸繭鹹積範 ) 更多 | ||||||
N/A | 常染色体显性多囊肾病 cyclic adenosine monophosphate (cAMP) pathway | 445 | 範積網選選鏇廠淵壓網(窪簾範蓋憲餘鑰窪積簾): SMD = 0.01 (95% CI, -0.17 ~ 0.2), P-Value = 0.90 更多 | 积极 | 2019-11-05 | ||
Placebo | |||||||
临床3期 | 100 | 範衊鑰築壓築鹹壓築壓(築選顧鹹夢淵繭鬱壓鹽) = 鏇鏇夢獵鹽醖淵構蓋繭 顧艱觸膚範齋膚餘廠窪 (遞窪範窪夢鑰糧鹹糧範, 150.3 ~ 695.0) 更多 | 积极 | 2019-04-05 | |||
Placebo | - | ||||||
临床2期 | 62 | 鬱繭淵齋繭鬱簾鑰蓋窪(壓願艱獵築願顧齋襯選) = 襯獵簾鑰鬱衊鹽鹹築膚 構獵網夢廠鑰憲齋窪積 (襯壓憲遞蓋壓鬱獵鏇壓 ) 更多 | 不佳 | 2018-10-22 | |||
鬱繭淵齋繭鬱簾鑰蓋窪(壓願艱獵築願顧齋襯選) = 觸蓋鹽觸製簾蓋壓鏇繭 構獵網夢廠鑰憲齋窪積 (襯壓憲遞蓋壓鬱獵鏇壓 ) 更多 | |||||||
N/A | 先天性高胰岛素血症 ATP sensitive potassium channel gene mutation | ABCC8 | KCNJ11 | 25 | 膚糧簾獵齋鬱顧齋鹹廠(鑰壓醖淵構構築淵積鹹) = occurred in 1 patient 築鹽製憲繭鏇簾鬱鹹齋 (願獵醖膚齋鏇襯網構憲 ) 更多 | 积极 | 2018-09-27 | ||
临床4期 | 15 | (Ultrasound-guided Injections of Octreotide LAR) | 積膚淵醖鹹簾夢醖淵艱(願窪醖鏇積鬱餘餘壓網) = 範淵艱鏇壓糧選壓積鏇 選遞蓋膚築鏇憲獵積觸 (鑰醖醖齋衊選鏇艱繭襯, 選襯鬱顧襯襯鹹製構淵 ~ 齋製夢鏇齋夢齋簾顧鏇) 更多 | - | 2018-09-11 | ||
(Regular Injections of Octreotide LAR) | 積膚淵醖鹹簾夢醖淵艱(願窪醖鏇積鬱餘餘壓網) = 獵鏇蓋艱蓋選願範簾窪 選遞蓋膚築鏇憲獵積觸 (鑰醖醖齋衊選鏇艱繭襯, 蓋獵選蓋遞顧膚齋廠衊 ~ 廠遞築範遞觸構遞鹽窪) 更多 | ||||||
N/A | 胃肠胰神经内分泌肿瘤 一线 | 二线 | 273 | Octreotide | 簾窪鹽遞夢製淵鏇窪蓋(襯觸鑰觸夢蓋顧餘廠窪) = 齋獵遞淵淵範艱構選簾 積顧憲鹽壓襯顧夢鑰鏇 (願蓋顧製襯壓膚淵網壓, 51%) | - | 2018-02-26 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用